Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Anna E. Tischer
Author Correction: A µ-opioid receptor superagonist analgesic with minimal adverse effects
Correction to: Nature https://doi.org/10.1038/s41586-026-10299-9 Published online 1 April 2026 In the version of this article initially published, there were typographical errors where in the Fig. 3e y-axis label and Fig.
Early life adversity increases striatal dopamine D1 receptor density and promotes social alcohol drinking in mice, especially males
Abstract The brain’s reward-processing circuitry remains sensitive to experience throughout early life and into adulthood, allowing individuals to adapt to their unique environments. Adverse experiences early in life can increase vulnerability to substance use disorders, likely through alterations to this circuitry. Yet, the precise neurobiological mechanisms by which early life adversity acts are incompletely characterized.
A µ-opioid receptor superagonist analgesic with minimal adverse effects
|
Abstract Developing safe and effective pain medications is an ongoing challenge for human health. Agonists for the µ-opioid receptor (MOR) are essential pain medications, but their high intrinsic efficacy also induces adverse side effects, including respiratory depression, constipation, tolerance, dependence, withdrawal and addiction1,2,3,4,5,6,7.
By Juan Gomez Verified, Juan Gómez, Emilya Ventriglia, Zachary Frangos, Agnieszka Sulima, Michael Robertson, Michael Sacco, Reece C. Budinich, Ilinca M. Giosan, Tongzhen Xie, Oscar Solis, Anna E. Tischer, Jennifer M. Bossert, Kiera E. Caldwell, Hannah Bonbrest, Amelie Essmann, Zelai M. Garçon-Poca, Shinbe Choi, Michael R. Noya, Feonil Limiac, Ali Arce, Grant C. Glatfelter, Margaret Robinson, LI YI CHEN, Angelina A. Mullarkey, Dain R. Brademan, Garrett A Enten, William Dunne, Cesar Quiroz, César Camacho Quiroz, Ingrid Schoenborn, Chae Bin Lee, Rana Rais, Daniel P. Holt, Robert F. Dannals, Ruth Hüttenhain, Sergi Ferré, Eugene A. Kiyatkin, Jordi Bonaventura, Yavin Shaham, Venetia Zachariou, Michael Baumann Verified, Georgios Skiniotis, Michael Michaelides
|
Nature
Verified
A reversible allosteric inhibitor of GlyT2 for neuropathic pain without on-target side effects - Nature Communications
Abstract Chronic neuropathic pain, caused by nerve damage or disease, is increasing in prevalence, but current treatments are ineffective and over-reliant on opioids. The neuronal glycine transporter, GlyT2, regulates inhibitory glycinergic neurotransmission and represents a promising target for new analgesics. However, most GlyT2 inhibitors cause significant side effects, in part due to irreversible inhibition at analgesic doses.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Anna E.
Contact Anna E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack